<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220399</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-1603_P1_DDI</org_study_id>
    <nct_id>NCT03220399</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2</brief_title>
  <official_title>Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navipharm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navipharm Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics and safety/tolerability between
      NVP-1603-1 and NVP-1603-2
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      pharmacokinetics and safety/tolerability between NVP-1603-1 and NVP-1603-2
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic interection</measure>
    <time_frame>0h - 48hrs</time_frame>
    <description>Area under the curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NVP-1603-1 (P)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: NVP-1603-1
1capsule, oral dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1603-2(T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: NVP-1603-2
1Tablet, oral dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1603-1and NVP-1603-2 (P+T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: NVP-1603-1, 1capsule and NVP-1603-2, 1Tablet co-adminstration (oral dosing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1603-1 (P)</intervention_name>
    <description>1capsule, single oral dosing</description>
    <arm_group_label>NVP-1603-1 (P)</arm_group_label>
    <other_name>NVP-1603-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1603-2 (T)</intervention_name>
    <description>1tablet, single oral dosing</description>
    <arm_group_label>NVP-1603-2(T)</arm_group_label>
    <other_name>NVP-1603-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1603-1 and NVP-1603-2 (P+T)</intervention_name>
    <description>1capsule and 1tablet co-administration, oral single dosing</description>
    <arm_group_label>NVP-1603-1and NVP-1603-2 (P+T)</arm_group_label>
    <other_name>NVP-1603-1 and NVP-1603-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men 19years of age or older at screening test.

          -  BMI of &gt;18.5kg/㎡ and &lt;27.0kg/㎡ subject, weight more than 50kg.

          -  Subject has signed and dated informed consent.

        Exclusion Criteria:

          -  Treatment with an investigational product (Phase I study or Biological study) within
             3month preceeding the first dose of study medication.

          -  History of (or presence) study medication absortion, distribution, metabolism(e.g.,
             liver/ductal, kidney, cardio-vascular, endocrine, respiratory, GI, hematology,
             oncology, CNS, musculo-skeletal) or related past medical/surgery history

          -  Current alcohol abuse.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy males (19years of age or older)</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Choi H Ju, Scientist</last_name>
    <phone>+8231-292-5436</phone>
    <email>hjchoi@navipharm.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shin D Sung, M.D</last_name>
    <email>dsshin@gilhospital.com</email>
  </overall_contact_backup>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

